This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
TFRC · Western blot design guide
TFRC Western Blot Planning Guide
Plan a TFRC Western blot around the catalog-observed 84.9 kDa band, image-backed PB9233 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
TFRC Western Blot Experimental Design Guide
Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 84.9 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 8-10% | |
| Positive control | Lung | |
| Negative control | Seminal vesicle |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 84.9 kDa |
| ⓘ | Localization | Cell membrane / Melanosome |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human / Mouse / Rat |
Section 1
Real Curated TFRC Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Bone marrow |
| Gel % | 8-10% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, standard transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | PB9233 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected TFRC Western Blot Band Size?
Use the product-observed 84.9 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 84.9 kDa | Matches the authoritative product WB observation. |
| 84.9 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected TFRC appearancePlan around 84.9 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 84.9 kDa; use this as the primary experimental expectation. |
| Calculated mass | 84.9 kDa from UniProt P02786; retain as context. |
| Gel selection | 8-10%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with PB9233. |
| Situation | Likely cause | Next action |
|---|---|---|
| 84.9 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing TFRC band
PB9233 · TFRC
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for TFRC Western blot
🧪Use Lung as the first positive-control candidate and Seminal vesicle as the HPA Not detected negative candidate.
Positive control: Lung (High)
Negative control: Seminal vesicle (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for TFRC
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Lung | Reported tissue cells | High | Protein (HPA) | HPA → |
| Bone marrow | Reported tissue cells | High | Protein (HPA) | HPA → |
| Placenta | Reported tissue cells | High | Protein (HPA) | HPA → |
| Adrenal gland | Reported tissue cells | Medium | Protein (HPA) | HPA → |
Section 3
Advanced TFRC Western Blot Tips
Deeper troubleshooting and optimisation questions for TFRC, answered from its protein features.
Which band should guide the blot?
Use 84.9 kDa, the observation attached to the authoritative PB9233 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 84.9 kDa expectation.
Which positive control should I start with?
Start with Lung, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Seminal vesicle as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 8-10% consistently across the quick facts, protocol table, and poster.
What transfer method to use for TFRC Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should PB9233 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
Compare only the supplied target-verified records: PMC13367347, PMC11612655, PMC11628347.
Boster reagents
TFRC Western Blot Reagents
Human/Mouse/Rat-reactive TFRC Western blot reagents with authoritative product imagery.
Real WB data
Anti-Transferrin Receptor/TFRC Antibody Picoband®
Cat # PB9233
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt P02786
- Human Protein Atlas — TFRC
- PB9233 product record
- PMC13367347 — Comparative Analysis of Ferroptosis- and Mitochondria-Related Genes in Ischemic Stroke via Bioinformatics Analysis and Experimental Validation.
- PMC11612655 — New insights into the mechanisms of iron absorption: Iron dextran uptake in the intestines of weaned pigs through glucose transporter 5 (GLUT5) and divalent metal transporter 1 (DMT1) transporters.
- PMC11628347 — Dual-Multivalent Aptamer-Based Drug Delivery Platform for Targeted SRC Silencing to Enhance Doxorubicin Sensitivity in Endometrial Cancer.